Nufenoxole (SC-27166) is an antidiarrhoeal drug which acts as a peripherally selective opioid agonist, in a similar manner to loperamide. while it is able to activate μ-opioid receptors, it fails to cross the blood–brain barrier and so has a selective action against diarrhoea without producing analgesic effects.[1][2][3][4][5]
See also
References
- ^ US RE29556E, Adelstein GW, "1,1-Diaryl-1-oxadiazol-alkylamines", issued 28 February 1978, assigned to G.D. Searle & Company
- ^ Dajani EZ, Bianchi RG, East PF, Bloss JL, Adelstein GW, Yen CH (December 1977). "The pharmacology of SC-27166: a novel antidiarrheal agent". The Journal of Pharmacology and Experimental Therapeutics. 203 (3): 512–26. PMID 411912.
- ^ Mackerer CR, Brougham LR, East PF, Bloss JL, Dajani EZ, Clay GA (December 1977). "Antidiarrheal and central nervous system activities of SC-27166 (2-[3 - 5 - methyl - 1, 3, 4 - oxadiazol - 2 - yl) - 3, 3 - diphenylpropyl] - 2 - azabicyclo [2.2.2]octane), a new antidiarrheal agent, resulting from binding to opiate receptor sites of brain and myenteric plexus". The Journal of Pharmacology and Experimental Therapeutics. 203 (3): 527–38. PMID 200732.
- ^ Niemegeers CJ, McGuire JL, Heykants JJ, Janssen PA (September 1979). "Dissociation between opiate-like and antidiarrheal activities of antidiarrheal drugs". The Journal of Pharmacology and Experimental Therapeutics. 210 (3): 327–33. PMID 480185.
- ^ Korey A, Zilm DH, Sellers EM (May 1980). "Dependence liability of two antidiarrheals, nufenoxole and loperamide". Clinical Pharmacology and Therapeutics. 27 (5): 659–64. doi:10.1038/clpt.1980.93. PMID 7371363. S2CID 35222789.